Pfizer has established an independent company to work on developing four drug candidates currently at the clinical trial stage.
The pharmaceutical giant has set up SpringWorks Therapeutics, which will work on developing treatments that were shelved due to budget constraints.
“SpringWorks Therapeutics will work on four drugs that were previously in development at Pfizer.“
Among the four is Nirogacesta, a potential treatment for desmoid tumours, and a candidate currently known as PF-0445784, which is being explored as a potential treatment for post-traumatic stress disorder.
The other drugs - Senicapoc and PD-0325901 - target hereditary xerocytosis and neurofibromatosis respectively.
Founder and president at SpringWorks Therapeutics Lara S Sullivan said the new company will "pursue the development of medicines across therapeutic areas, focused on diseases where there is an urgent need and the potential for the greatest impact for patients".
SpringWorks has secured series A funding of $103 million (76 million pounds), with Pfizer itself one of the main investors in the new business.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical